Diadema Partners’s Denali Therapeutics DNLI Stock Holding History

Diadema Partners’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-60,000	Closed	-$1.22M	–	123
2024 Q4	$1.22M	Buy	+60,000	New	+$1.54M	0.52%	48

Other funds holding DNLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Diadema Partners's DNLI Position: Q1 2025 in Review

Diadema Partners sold out of Denali Therapeutics (DNLI) in Q1 2025, closing a stake of 60,000 shares — an estimated $1.22M sold.

Diadema Partners first reported a position in DNLI in Q4 2024 and held it in 1 quarter. The position peaked at $1.22M in Q4 2024. 222 funds tracked by Wall St. Rank hold DNLI as of Q1 2025.

Diadema Partners reported no remaining Denali Therapeutics position as of Q1 2025 after selling out during the quarter.
Diadema Partners sold 60,000 Denali Therapeutics shares in Q1 2025, an estimated $1.22M.
Diadema Partners first reported a position in Denali Therapeutics in Q4 2024 and held it in 1 quarter.
Diadema Partners's Denali Therapeutics position peaked at $1.22M in Q4 2024.
222 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2025.

Based on Diadema Partners's 13F filing for Q1 2025, filed 15 May 2025.